Bristol-Myers Squibb Co. (BMY) To Go Ex-Dividend on October 5th
Bristol-Myers Squibb Co. (NYSE:BMY) declared a quarterly dividend on Wednesday, August 3rd. Shareholders of record on Friday, October 7th will be given a dividend of 0.38 per share by the biopharmaceutical company on Tuesday, November 1st. This represents a $1.52 dividend on an annualized basis and a yield of 2.82%. The ex-dividend date of this dividend is Wednesday, October 5th.
Bristol-Myers Squibb (NYSE:BMY) opened at 53.87 on Friday. The firm has a 50-day moving average price of $57.24 and a 200-day moving average price of $67.13. Bristol-Myers Squibb has a 1-year low of $53.76 and a 1-year high of $77.12. The company has a market capitalization of $90.01 billion, a P/E ratio of 31.50 and a beta of 0.61.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The firm had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.60 billion. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.53 EPS. On average, analysts forecast that Bristol-Myers Squibb will post $2.62 EPS for the current fiscal year.
Several research analysts have commented on BMY shares. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a report on Wednesday, July 6th. Citigroup Inc. dropped their price objective on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, August 3rd. Leerink Swann reissued a “buy” rating and issued a $85.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, July 29th. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 price objective on the stock in a research note on Monday, July 25th. Finally, Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research note on Wednesday, July 13th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $69.91.
In other news, Director Lamberto Andreotti sold 23,200 shares of the company’s stock in a transaction that occurred on Friday, July 8th. The stock was sold at an average price of $74.45, for a total value of $1,727,240.00. Following the completion of the transaction, the director now directly owns 380,099 shares of the company’s stock, valued at $28,298,370.55. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.24% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. WESPAC Advisors SoCal LLC raised its position in Bristol-Myers Squibb by 5.1% in the second quarter. WESPAC Advisors SoCal LLC now owns 1,538 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 75 shares in the last quarter. Krilogy Financial LLC raised its position in Bristol-Myers Squibb by 30.9% in the second quarter. Krilogy Financial LLC now owns 2,467 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 583 shares in the last quarter. Keeley Asset Management Corp acquired a new position in Bristol-Myers Squibb during the second quarter valued at about $218,000. MEMBERS Trust Co acquired a new position in Bristol-Myers Squibb during the second quarter valued at about $223,000. Finally, Highland Private Wealth Management raised its position in Bristol-Myers Squibb by 4.6% in the second quarter. Highland Private Wealth Management now owns 3,720 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 165 shares in the last quarter. 72.91% of the stock is owned by institutional investors.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.